The statement that MM cell-originated exosomes provoked the stimulation of EGFR systems in MSCs and OC precursors implies the opportunity to employ drugs able to inhibit EGFR, such as gefitinib and erlotinib, and to alter the communication between MM plasma cells and the BM milieu to inhibit the onset of bone lesions. Here, EGFR is linked to Miyoshi myopathy.